Quality of life in randomized trials of cytotoxic or hormonal treatment of advanced breast cancer. Is there added value?

Breast Cancer Research and Treatment

Volumn 87, Issue 3, 2004, Pages 233-243

  Fossati, Roldano ^a   Confalonieri, Carlo ^a   Mosconi, Paola ^a   Pistotti, Vanna ^a   Apolone, Giovanni ^a  

^a MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

Author keywords

advanced breast cancer; cytotoxic hormonal treatment; quality of life

Indexed keywords

CYTOTOXIC AGENT; HORMONE;

ADVANCED CANCER; ARTICLE; BREAST CANCER; CANCER GROWTH; CANCER SURVIVAL; HORMONAL THERAPY; HUMAN; METHODOLOGY; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; FEMALE; HUMANS; NEOPLASM METASTASIS; PALLIATIVE CARE; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIALS; RESEARCH DESIGN;

EID: 8644249765     PISSN: 01676806     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10549-004-8694-y     Document Type: Article

References (66)

1. Tassinari D: Surrogate end points of quality of life assessment: have we really found what we are looking for? Health Qual Life Outcomes 1(1): 71, 2003
2. Guyatt GH, Feeny DH, Patrick DL: Measuring health related quality of life. Ann Intern Med 118: 622-629, 1993
3. Bottomley A, Therasse P: Quality of life in patients undergoing systemic therapy for advanced breast cancer. Lancet Oncol 3: 620-628, 2002
4. Goodwin PJ, Black JT, Bordeleau LJ, Ganz PA: Health-related quality-of-life measurement in randomized clinical trials in breast cancer-taking stock. J Natl Cancer Inst 95: 263-281, 2003
5. Chassany O, Sagnier P, Marquis P et al.: Patient reported outcomes: the example of health related quality of life - a European guidance for the improved integration of HRQoL assessment in the drug regulatory process. Drug Inf J 36: 209-238, 2002
6. Jadad AR: Randomized controlled trias. A user's guide. BMJ Books, BMA House, Tavistock Square, London WC1H 9JR, 1998
7. Bennet JM, Muss HB, Doroshow JH et al.: A randomized multicenter trial comparing mitoxantrone, cyclophosphamide, and fluorouracil with doxorubicin, cyclophosphamide, and fluorouracil in the therapy of metastatic breast carcinoma. J Clin Oncol 6: 1611-1620, 1988
8. Bernhard J, Castiglione-Gertsch M, Hsu Schmitz SF et al.: Quality of life in postmenopausal patients with breast cancer after failure of tamoxifen: formestane versus megestrol acetate as second-line hormonal treatment. Eur J Cancer 35: 913-920, 1999
9. Bertsch LA and Donaldson G: Quality of life analyses from vinorelbine (Navelbine) clinical trials of women with metastatic breast cancer. Semin Oncol 22 (Suppl 5): 45-54, 1995
10. Bishop JF, Dewar J, Toner GC et al.: Initial paclitaxel improves outcome compared with CMFP combination chemotherapy as front-line therapy in untreated metastatic breast cancer. J Clin Oncol 17: 2355-2364, 1999
11. 2) in the FEC regimen significantly increases response rates. An international randomised phase III study in metastatic breast cancer. Ann Oncol 8: 155-162, 1997
12. Buzdar AU, Jones SE, Vogel CL et al.: A phase III trial comparing anastrozole (1 and 10 milligrams), a potent and selective aromatase inhibitor, with megestrol acetate in postmenopausal women with advanced breast carcinoma. Cancer 79: 730-739, 1997
13. Chan S, Friedrichs K, Noel D et al.: Prospective randomised trial of docetaxel versus doxorubicin in patients with metastatic breast cancer. J Clin Oncol 17: 2341-2354, 1999
14. Coates A, Gebski V, Stat M et al.: Improving the quality of life during chemotherapy for advanced breast cancer. A comparison of intermittent and continuous treatment strategies. N Engl J Med 317: 1490-1495, 1987
15. Coates A, Gebski V: Quality of life studies of the Australian New Zealand Breast Cancer Trial Group: approaches to missing data. Statist Med 17: 533-540, 1998
16. Dombernowsky P, Falkson SG, Leonard R et al.: Letrozole, a new oral aromatase inhibitor for advanced breast cancer: double-blind randomised trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate. J Clin Oncol 16: 453-461, 1998
17. Fraser SCA, Dobbs HJ, Ebbs SR et al.: Combination or mild single agent chemotherapy for advanced breast cancer? CMF vs epirubicin measuring quality of life. Br J Cancer 67: 402-406, 1993
18. Goss PE, Winer EP, Tannock IF et al.: Randomised phase III trial comparing the new potent and selective third-generation aromatase inhibitor vorozole with Megestrol acetate in postmenopausal advanced breast cancer patients. J Clin Oncol 17: 52-63, 1999
19. Hakamies-Blomqvist L, Luoma ML, Sjostrom J et al.: Quality of life in patients with metastatic breast cancer receiving either docetaxel or sequential methotrexate and 5-fluorouracil. A multicentre randomised phase III trial by the Scandinavian Breast Group. Eur J Cancer 36: 1411-1417, 2000
20. Harper-Wynne C, English J, Meyer L et al.: Randomized trial to compare the efficacy and toxicity of cyclophosphamide, methotrexate and 5-fluorouracil (CMF) with methotrexate mitoxantrone (MM) in advanced carcinoma of the breast. Br J Cancer 81: 316-322, 1999
21. Hayes DF, Van Zyl JA, Hacking A et al.: Randomised comparison of tamoxifen and two separate doses of toremifene in postmenopausal patients with metastatic breast cancer. J Clin Oncol 13: 2556-2566, 1995
22. Heidemann E, Souchon R, Stoger H et al.: First-line monochemotherapy with mitoxantrone versus combination with fluorouracil, epirubicin and cyclophosphamide in high-risk metastatic breast cancer: a prospective randomized multicenter clinical trial. Onkologie 23: 54-59, 2000
23. Jassem J, Pienkowski T, Pluzanska A et al.: Doxorubicin and paclitaxel versus fluorouracil, doxorubicin, and cyclophosphamide as first-line therapy for women with metastatic breast cancer: final results of a randomized phase III multicenter trial. J Clin Oncol 19: 1707-1715, 2001
24. Joensuu H, Holli K, Heikkinen M et al.: Combination chemotherapy versus single-agent therapy as first- and second-line treatment in metastatic breast cancer: a prospective randomized trial. J Clin Oncol 16: 3720-3730, 1998
25. Jones S, Winer E, Vogel C et al.: Randomized comparison of vinorelbine and melphalan in anthracycline-refractory advanced breast cancer. J Clin Oncol 13: 2567-2574, 1995
26. Jonat W, Howell A, Blomqvist C et al.: A randomized trial comparing two doses of the new selective aromatase inhibitor anastrozole (Arimidex) with megestrol acetate in postmenopausal patients with advanced breast cancer. Eur J Cancer 32A: 404-412, 1996
27. Kaufmann M, Bajetta E, Dirix LY et al.: Exemestane is superior to megestrol acetate after tamoxifen failure in postmenopausal women with advanced breast cancer: results of a phase III randomized double-blind trial. J Clin Oncol 18: 1399-1411, 2000
28. Kloke O, Klaassen U, Oberhoff C et al.: Maintenance treatment with medroxyprogesterone acetate in patients with advanced breast cancer responding to chemotherapy: results of a randomized trial. Breast Cancer Res Treat 55: 51-59, 1999
29. Kornblith AB, Hollis DR, Zuckerman E et al.: Effect of megestrol acetate on quality of life in a dose-response trial in women with advanced breast cancer. J Clin Oncol 11: 2081-2089, 1993
30. Kramer JA, Curran D, Piccart M et al.: Randomised trial of paclitaxel versus doxorubicin as first-line chemotherapy for advanced breast cancer: quality of life evaluation using the EORTC QLQ-C30 and the Rotterdam Symptom Checklist. Eur J Cancer 36: 1488-1497, 2000
31. Kramer JA, Curran D, Piccart M et al.: Identification and interpretation of clinical and quality of life prognostic factors for survival and response to treatment in first-line chemotherapy in advanced breast cancer. Eur J Cancer 36: 1498-1506, 2000
32. Nabholtz J-M, Senn HJ, Bezwoda WR et al.: Prospective randomized trial of docetaxel versus mitomycin plus vinblastine in patients with metastatic breast cancer progressing despite previous anthracycline-containing chemotherapy. J Clin Oncol 17: 1413-1424, 1999
33. Norris B, Pritchard KI, Myles J et al.: Phase III comparative study of vinorelbine combined with doxorubicin versus doxorubicin alone in disseminated metastatic/recurrent breast cancer: National Cancer Institute of Canada Clinical Trials Group Study MA8. J Clin Oncol 18: 2385-2394, 2000
34. Paridaens R, Biganzoli L, Bruning P et al.: Paclitaxel versus doxorubicin as first-line single-agent chemotherapy for metastatic breast cancer: a European Organization for Research and Treatment of Cancer randomized study with cross-over. J Clin Oncol 18: 724-733, 2000
35. Riccardi A, Tinelli C, Brugnatelli S et al.: Doubling of the epirubicin dosage within the 5-fluorouracil epirubicin and cyclophosphamide regimen: a prospective, randomized, multicentric study on antitumor effect and quality of life in advanced breast cancer. Inter J Oncol 16: 769-776, 2000
36. Richards MA, Hopwood P, Ramirez AJ et al.: Doxorubicin in advanced breast cancer: influence of schedule on response, survival and quality of life. Eur J Cancer 28A: 1023-1028, 1992
37. Stewart DJ, Evans WK, Shepherd FA et al.: Cyclophosphamide and fluorouracil combined with mitoxantrone versus doxorubicin for breast cancer: superiority of doxorubicin. J Clin Oncol 15: 1897-190, 1997
38. Sjostrom J, Blomqvist C, Mouridsen H et al.: Docetaxel compared with sequential methotrexate and 5-fluorouracil in patients with advanced breast cancer after anthracycline failure: a randomised phase III study with crossover on progression by the Scandinavian Breast Group. Eur J Cancer 35: 1194-1201, 1999
39. Tannock IF, Boyd NF, DeBoer G et al.: A randomised trial of two dose levels of cyclophosphamide, methotrexate, and fluorouracil chemotherapy for patients with metastatic breast cancer. J Clin Oncol 6: 1377-1387, 1988
40. Heidemann E, Stoeger H, Souchon R et al.: Is first-line single-agent mitoxantrone in the treatment of high-risk metastatic breast cancer patients as effective as combination chemotherapy? No difference in survival but higher quality of life were found in a multicenter randomised trial. Ann Oncol 13: 1717-1729, 2002
41. Sledge GW, Neuberg D, Bernardo P et al.: Phase III trial of doxorubicin, paclitaxel, and the combination of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast cancer: an Intergroup trial (E1193). J Clin Oncol 21: 588-592, 2003
42. Nabholtz JM, Falkons C, Campos D et al.: Docetaxel and doxorubicin compared with doxorubicin and cyclophosphamide as first-line chemotherapy for metastatic breast cancer: results of a randomized, multicenter, phase III trial. J Clin Oncol 21: 968-975, 2003
43. Osborne CK, Pippen J, Jones SE et al.: Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: results of a North American trial. J Clin Oncol 20: 3386-3395, 2002
44. Howell A, Roberstron JFR, Quaresma Albano J et al.: Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment. J Clin Oncol 20: 3396-3403, 2002
45. Cardoso S, Di Leo A, Lohrisch C et al.: Second and subsequent lines of chemotherapy for metastatic breast cancer: what did we learn in the last two decades? Ann Oncol 13: 197-207, 2002
46. Ramirez AJ, Towlson KE, Leaning MS et al.: Do patients with advanced breast cancer benefit from chemotherapy? Br J Cancer 78: 1488-1494, 1998
47. Coates A, Gebski V, Signorini D et al.: Prognostic value of Quality-of-Life scores during chemotherapy for advanced breast cancer. J Clin Oncol 10: 1833-1838, 1992
48. Bernhard J, Thurlimann B, Hsu Schmitz S-F et al.: Defining clinical benefit in postmenopausal patients with breast cancer under second-line endocrine treatment: does qualità of life matter? J Clin Oncol 17: 1672-1679, 1999
49. Kaasa S, Mastekaasa A, Naess S: Quality of life of lung cancer patients in a randomized clinical trial evaluated by psychosocial well-being questionnaire. Ann Oncol 27: 335-342, 1988
50. Glimelius B, Hoffmar K, Olafsdottir M et al.: Quality of life during cytostatic therapy for advanced symptomatic colorectal carcinoma: a randomised comparison of two regimens. Eur J Cancer Clin Oncol 25: 829-835, 1989
51. Fossati R, Confalonieri C, Apolone G et al.: Does a drug do better when is new? Ann Oncol 13: 470-473, 2002
52. Coates AS, Hurny C, Peterson HF et al.: Quality-of-life scores predict outcome in metastatic but not early breast cancer. J Clin Oncol 18: 3768-3774, 2000
53. McEvoy MD, McCorkle R: Quality of life issues in patients with disseminated breast cancer. Cancer 66: 1416-1421, 1990
54. Seidman AD, Portenoy R, Yao T-J et al.: Quality of life in phase II trials: a study of methodology and predictive value in patients with advanced breast cancer treated with paclitaxel plus granulocyte colony-stimulating factor. J Natl Cancer Inst 87: 1316-1322, 1995
55. Cohen L, de Moor C, Amato RJ: The association between treatment-specific optimism and depressive symtomatology in patients enrolled in a phase I cancer clinical trial. Cancer 91: 1949-1955, 2001
56. Hakamies-Blomqvist L, Luoma M-L, Sjostrom J et al.: Timing of quality of life (QoL) assessments as a source of error in oncological trails. J Adv Nursing 35: 709-716, 2001
57. Bernhard J, Cella DF, Coates A et al.: Missing quality of data in cancer clinical trials: serious problems and challenges. Statist Med 17: 517-532, 1998
58. Fairclough DL, Gelber RD: Quality of life: statistical issues and analysis. In: Spilker B, (ed.) Quality of life and Pharmacoeconomics in Clinical Trials. Lippincott-Raven Publishers, Philadelphia, pp. 427-436, 1996
59. Simes J, Greatorex V, Gebski VJ: Practical approaches to minimize problems with missing quality of life data. Statist Med 17: 725-737, 1998
60. Fairclough DL, Peterson HF, Cella D et al.: Comparison of several model-based methods for analysing incomplete quality of life data in cancer clinical trials. Statist Med 17: 781-796, 1998
61. Winer EP: Quality-of-life research in patients with breast cancer. Cancer 74: 410-415, 1994
62. Cote I, Gregoire JP, Moisan J: Health-related quality of life measurement in hypertension. Pharmacoeconomics 18: 435-450, 2000
63. Apolone G, De Carli G, Brunetti M et al.: Health-related quality of life (HR-QOL) and regulatory issues. An assessment of the European Agency for the Evaluation for Medicinal Products (EMEA) recommendations on the use of HR-QOL measures in drug approval. Pharmaeconomics 19: 187-195, 2001
64. European Medicines Evaluation Agency. Note for guidance on evaluation of anticancer medicinal products in man. CPMP/EWP/205/95 rev.1 http://www.emea.eu. int/pdfs/human/ewp/020595en.pdf
65. Beitz J, Gnecco C, Justice R: Quality-of-Life end points in cancer clinical trial: the U.S. Food and Drug administration perspective. Monogr Natl Cancer Inst 20: 7-9, 1996
66. Carelle N, Piotto E, Bellanger A et al.: Changing patient perceptions of the side effects of cancer chemotherapy. Cancer 95: 155-163, 2002